Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

Published:2015-04 Issue:4 Volume:16 Page:436-446
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hu Xi-Chun,Zhang Jian,Xu Bing-He,Cai Li,Ragaz Joseph,Wang Zhong-Hua,Wang Bi-Yun,Teng Yue-E,Tong Zhong-Sheng,Pan Yue-Yin,Yin Yong-Mei,Wu Chang-Ping,Jiang Ze-Fei,Wang Xiao-Jia,Lou Gu-Yin,Liu Dong-Geng,Feng Ji-Feng,Luo Jian-Feng,Sun Kang,Gu Ya-Jia,Wu Jiong,Shao Zhi-Min

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Triple-negative breast cancer;Foulkes;N Engl J Med,2010

2. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007

3. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design;Kassam;Clin Breast Cancer,2009

4. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis;Clark;Core Evid,2014

5. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer;Ma;Breast Cancer Res Treat,2013

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer treatment-induced bone loss;The Korean Journal of Internal Medicine;2024-09-01

2. Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression;Cancers;2024-08-08

3. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization;Phytomedicine;2024-07

4. Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer;Cancer Biology & Medicine;2024-05-16

5. Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trial;2024-04-11